Financings

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

By The Northwire Desk — AI Analysis Mar 05, 2026 · 15:45 ADK · 0.31 Diagnos Inc.

ADK · Price

Diagnos Inc. announced amendments to its $510,000 unsecured convertible debentures, extending maturity to March 1 2027 and lowering the conversion price from $0.38 to $0.32 while maintaining a 10% annual interest rate.
The company also extended the expiry of 8,333,333 stock warrants (exercise price $0.40) from March 20 2026 to September 5 2026.
Both amendments remain subject to TSX Venture Exchange approval and will be formalized through execution of documentation.

Debenture Amendment
Original aggregate amount: $510,000 unsecured convertible debentures.
Maturity date extended from March 1 2026 to March 1 2027.
Conversion price reduced from $0.38 per share to $0.32 per share.
Annual interest rate remains at 10% for the extended period (Mar 1 2026 – Mar 1 2027).
All other terms unchanged.
Related Party Disclosure
Insider André Larente holds 2 debentures with a nominal aggregate value of $20,000.
Amendment exempt from MI 61‑101 valuation and minority approval requirements (fair market value < 25% of market cap).
Warrant Extension
8,333,333 stock warrants issued in the September 20 2024 private placement.
Original expiry: March 20 2026; extended to September 5 2026.
Exercise price unchanged at $0.40 per common share.
Regulatory Conditions
Amendments subject to acceptance by the TSX Venture Exchange and execution of formal documentation.
Company will issue a follow‑up press release only if the Exchange rejects any amendment.

(No direct quotes were provided in the release.)

More from Diagnos Inc.